Teva Pharmaceutical Industries Limited (TEVA) is experiencing a significant turnaround, with shares surging over 130% in the past year. Analysts are optimistic, with 12 out of 15 rating the stock as a “buy” or “strong buy.” Key catalysts driving this momentum include the anticipated FDA approval of Teva’s long-acting olanzapine formulation for schizophrenia, which could enhance treatment adherence and boost sales significantly.
Additionally, Teva’s specialty drugs, particularly Austedo, are showing strong commercial growth, with projected sales increasing to between $2.4 billion and $2.55 billion this year. The company’s robust biosimilar pipeline, including upcoming launches that could challenge major competitors, further positions Teva for potential gains.
For market professionals, the implication is clear: Teva’s combination of a de-risked pipeline and attractive valuation—trading at a forward earnings multiple of just 11.7—makes it a compelling stock to watch. The potential for reaching $40 hinges on successful product launches and sustained sales growth in its specialty and biosimilar segments.
Source: fool.com